Clinical Trial Update: Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ALECSAT as an add-on to standard care for glioblastoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• ALECSAT

Snippet

Sponsor: CytoVac A/S | Conditions: Glioblastoma | Phase 2 | Status: COMPLETED